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Abstract, CHAPTER I: Introduction and previous work



The thesis entitled “Studies directed towards the total synthesis of azaspiracid” is divided into three chapters.
CHAPTER-I: Chapter I deals with the introduction and previous approaches toward the synthesis of azaspiracid-1 (mainly ABCD ring framework of azaspiracid-1)
CHAPTER-II: Chapter II is divided into two sections.
SECTION A: This section deals with the synthesis of the ABCD ring framework of the first proposed structure of azaspiracid-1 by connecting two fragments by formation of C-10 and C-11 bond.
SECTION B: Synthesis of C-5 to C-20 fragment of azaspiracid-1 by connecting C-5C-9 and C-10C-20 fragments 
CHAPTER-III: Chapter III is divided into two sections.
SECTION A: This section deals with the synthetic efforts toward the ABCD ring framework of the revised structure of azaspiracid-1 by connecting two fragments via C-10 and C-11 bond formation 
SECTION B: This section deals with the synthetic efforts toward the ABCD ring framework of the revised structure of azaspiracid-1 by unification of two fragments via C-8 and C-9 bond formation

INTRODUCTION:
Azaspiracid is a marine natural product isolated from the blue mussel Mytius edulis collected in Killary Harbour, Ireland. The first episode of azaspiracid poisoning was reported by McMahon and Silke in 1996 in the Netherlands, where people who ate mussels imported from Ireland (Killary Bay) complained of gastrointestinal symptoms and serious diarrhoea. Yasumoto and co-workers reported the isolation of azaspiracid-1 (containing single azaspiro ring and one carboxylic acid groups) and proposed the structure. Ten more closely related analogues of azaspiracid were isolated namely azaspiracid-2, azaspiracid-3, azaspiracid-4, azaspiracid-5, azaspiracid-6, azaspiracid-7, azaspiracid-8, azaspiracid-9, azaspiracid-10 and azaspiracid-11 (Figure 1). Azaspiracid 1-3 show toxicity in vitro in mice at doses of 0.2, 0.11 and 0.14 mg/kg respectively. The human and environmental hazard posed by azaspiracid has drawn a lot of attention. Its effect on humans is different than other marine toxins. The symptoms resemble those of diarrhetic shellfish poisoning (DSP) but the major DSP toxins such as okadaic acid and dinophysistoxins are very low in the contaminated mussels. Extensive bioassays performed on azaspiracid have demonstrated that the effects of the toxins when administered to mice are distinct from those caused by other marine toxins, hence, azaspiracid poisoning (AZP) defines a new type of neuroxicity associated with this environmental contaminant. 
Mass spectrometric and extensive NMR spectroscopic analysis revealed that azaspiracid-1 had an unprecedented array of polycyclic, spirofused ring systems, an amino acid residue with 40 carbon backbone with 47 carbons, 20 stereocenters and 9 rings with three spirolinkages. Azaspiracid-1 contains a trioxadispiroketal system fused to tetrahydrofuran moiety (ABCD ring), an azaspiro ring fused to a 2,9-dioxabicyclo[3.3.1]nonane system (FGHI ring), six membered hemiketal bridge (E ring) and γ,δ-unsaturated carboxylic acid. The complex structural framework, stereochemical ambiguity, unique architecture, biological activity and scarcity make it an attractive and challenging target for the synthetic chemist to synthesize it. Total synthesis of azaspiacid-1 by Nicolaou et al. revealed that the first structure proposed by Yasumoto et al. was incorrect. Nicolaou and co-workers proposed a revised structure and synthesized the same which had physical characteristics that matched with the natural product (Figure 2). 
The complex structural framework and unique stereochemistry encouraged for synthesizing azaspiracid. The focus was mainly on the stereoselective synthesis of the ABCD ring framework of azaspiracid-1 (first proposed by Yasumoto et al. and later revised by Nicolaou et al.).


Name      R1      R2    R3      R4
AZA-1 :  H     H     Me    H
AZA-2 :  H     Me   Me    H
AZA-3 :  H      H     H      H
AZA-4 :  OH   H     H      H
AZA-5 :  H      H     H      OH
AZA-6 :  H      Me   H      H
AZA-7 :  OH   H     Me    H
AZA-8 :  H      H     Me    OH
AZA-9 :  OH   Me   H      H
AZA-10: H      Me   H      OH
AZA-11: OH   Me   Me    H



CHAPTER II: Synthesis of the ABCD framework of the first proposed structure of the azaspiracid-1 (AZA-1).
Section A: This section deals with the synthesis of the ABCD ring framework of the first proposed structure of azaspiracid-1 by connecting two fragments by formation of C-10 and C-11 bond.

Retrosynthetic analysis: 
Scheme 1 depicts the disconnection of AZA-1 (1) into two fragments ABCD (3) and EFGHI (4). This section deals with the synthesis of the ABCD ring framework by connecting C-5–C-10 and C-11–C-20 fragments. The ABCD ring framework (3) of azaspiracid-1 could be obtained via double spiroketalization of 1,4-diketo compound 5 under acidic condition (Scheme 2). The 1,4-diketo compound 5 could in turn be obtained by a Stetter reaction between ,-unsaturated ketone 8 and unsaturated aldehyde 6 or aldehyde 7. The unsaturated ketone 8 was envisioned to be derived from compound 9 through a standard series of reactions. The D ring that is 2,5-trans tetrahydrofuran ring would be easily obtained from compound 11 via compound 10. The alkyne 11 could be prepared from lactone 12 which would be easily synthesized from epoxy alcohol 13 through routine course of reaction reactions. 
Moreover, the 1,4-diketo compound 5 was anticipated to be prepared by dithiane coupling between iodo derivative 14 and dithiane derivatives (15/16) in the presence of a base. The organolithium compound prepared from 14 could also be coupled to aldehyde 6 to give 1,4-diketo compound 5 after functional group transformations (Scheme 2). 

Retrosynthesis of azaspiracid-1

Synthesis of C-11–C-20 fragment of ABCD ring
1,3-propanediol 17 was protected as its mono benzyl ether 18 and the hydroxyl group was oxidized using PCC to afford aldehyde 19. Wittig oleifination of 19 produced trans ,-unsaturated ester 20. DIBAL-H reduction of the ester group of compound 20 furnished allyl alcohol 21, which upon Sharpless asymmetric epoxidation using D-(–)-DIPT gave epoxy alcohol 13. The epoxy alcohol was then transformed to the chiral secondary allyl alcohol 23 via a two steps sequence (TPP, I2, imidazole followed by Zn, NaI). Compound 23 was then treated with NBS and ethyl vinyl ether to form bromo acetal 24, which after 
Disconnection between C-10 and C-11 bond
 stereoselective radical cyclization in refluxing benzene (n-Bu3SnH, AIBN) furnished the lactol ether 25. Jones oxidation of 25 led to the formation of lactone 12, which on treatment with CCl4 and TPP afforded methylenedichloro compound 26. The compound 26 on reductive elimination process using Li sand furnished the acetylenic compound 27 with concomitant debenzylation. The acetonide 11 prepared from diol 27 (2,2-DMP, p-TSA) was 
used for opening of chiral epoxide 28 (n-BuLi, BF3.OEt2, – 78 °C) to give homo propargyl alcohol compound 29 (Scheme3). 

The reduction of triple bond of 29 to trans-olefin 10 was achieved using LAH in refluxing diglyme and THF mixture. Tosylation (TsCl, Et3N) of 10 furnished compound 30 which was then subjected to Sharpless asymmetric dihydroxylation (AD-mix-) to yield compound 32 via diol 31. MOM protection of the secondary hydroxyl group of 32 followed by acetonide deprotection using (2N HCl) gave 33. The primary hydroxyl group of diol was selectively tosylated (TsCl, pyridine) to yield 34, subsequent oxidation of secondary hydroxyl group under Swern condition afforded ,-unsaturated ketone 8 by concomitant elimination of OTs group (Scheme 4).



Synthesis of iodo derivative 14 (C-11C-20 fragments)
The hydroxyl groups of diol 33 were protected as TBS ethers (TBS-OTf, 2,6-lutidine) to yield 35. Selective deprotection of the primary TBS group under acidic condition gave alcohol 36, subsequent iodination (I2, TPP, imidazole) of primary hydroxyl group furnished compound 37. Moreover, 37 was also prepared from 34 in two steps involving protection of hydroxyl group as its TBS ether, followed by tosyl displacement with NaI. Alternatively, the diol 33 was subjected to selective protection of primary alcohol as its TBS ether (TBS-Cl, Im.) to furnish 38. Protection of the secondary hydroxyl group as its TBDPS ether (TBDPS-Cl, Im.) gave 39. The TBS group in 39 was selectively deprotected (p-TSA) to give 40 which was then converted to iodo compound 41 (Scheme 5).


Synthesis of C-5–C-9 and C-5–C-10 carbon fragments
The unsaturated aldehyde 44 was prepared from (S)-malic acid (Scheme 6). Thus diethyl ester of (S)-malic ester was transformed by a sequence of reactions into aldehyde 42. Which was transformed to acetylenic compound 43 using Corey-Fuchs reaction (CBr4, TPP followed by EtMgBr). Treatment of 43 with LDA and paraformaldehyde furnished propargyl alcohol, which on PCC oxidation gave aldehyde 44. The aldehyde 7 was prepared from aldehyde 42 by subjecting it to Wittig olefination followed by Michael addition of thiophenol to the resulting ,-unsaturated ester and DIBAL-H reduction of ester group. 



The aldehyde 48 was obtained from epoxide 46 (Scheme 6). Opening of epoxide in 46 with THP protected propargyl alcohol 45 under Yamaguchi conditions gave propargyl alcohol 47. Protection of secondary hydroxyl group as its MOM ether, deprotection of THP group and oxidation of resulting primary alcohol using PCC reagent afforded aldehyde 48 (Scheme 6). The dithianes (15/49) were prepared from aldehydes (44/48) respectively by reaction with 1,3 propanedithiol under acidic condition (Scheme 6).
When the aldehydes 44/ 48/ 7 were treated with ,-unsaturated ketone 8 separately following Stetter protocol, the desired 1,4-diketo compound was not obtained, instead, a complex mixture resulted in all the cases (Scheme 7).
Also when the dithiane derivatives 15 and 49 were treated with iodo compounds 37 and 41 respectively, in the presence of different bases complex product mixture resulted and none of the required compound was isolated (Scheme 7).
The iodo compounds 37 and 41 on treatment with t-BuLi afforded the corresponding organolithium compounds which were used in the coupling with aldehydes 44 and 48 respectively but unfortunately failed to yield the required product (Scheme 7).

Section B: Synthesis of C-5 to C-20 fragment of azaspiracid-1 by connecting C-5C-9 and C-10C-20 fragments. 

Retrosynthetic analysis shown in Scheme 8
Disconnection between C-9 and C-10 carbons


New strategy was planned to synthesize the ABCD ring framework (3) of azaspiracid-1 from 1,4-diketo compound 51 (Scheme 8). 1,4-diketo compound 51 could be obtained by coupling between keto-aldehyde 53 and acetylelic compound 52. The keto-aldehyde 53 was assessed easily from 54 which in turn could be obtained from 55 following routine course of reactions. 

Synthesis of C-10C-20 fragment
The acetylenic compound 55 (Scheme 9) was obtained from 1,4-butanediol following the same sequence of reactions used to prepare 27 as shown in Scheme 3. Acetylenic diol 55 was protected as its TBDPS ether, epoxide opening under Yamaguchi conditions produced homo propargyl alcohol 57. The triple bond was then reduced to trans double bond with LAH in refluxing diglyme and THF mixture with concomitant deprotection of TBDPS groups, to afford a triol, which on acetonide protection of 1,4-diol afforded 54. Compound 54 was transformed into compound 58 as described earlier (Scheme 4). Protection of secondary hydroxyl group of 58 as its TBS ether followed by acetonide deprotection under mild acidic condition produced 1,4-diol, which was then oxidized to the keto-aldehyde 53 under Swern oxidation conditions (Scheme 9).


Coupling of keto-aldehyde and acetylene fragments
The keto-aldehyde 53 on reaction with lithium acetylide from 43 furnished compound 59 (Scheme 10). Partial hydrogenation produced cis-olefin 60. The DMP oxidation of secondary hydroxyl group provided the 1,4-diketo compound 61, the precursor for the ABCD ring framework of azaspiracid-1. When the diketo compound 61 was treated with TMS-OTf or CSA to effect cyclization, decomposition of starting material was observed. Then the keto-aldehyde 53 was treated with acetylenic compound 50 (prepared from TMS-acetylene and chiral epoxide 28 as shown in Scheme 6), to yield the compound 62 (Scheme 10). The synthetic efforts were terminated at this stage since Nicolaou and co-workers by then reported that the structure of azaspiracid-1 as proposed by Yasumoto was not correct. They proposed a revised structure and synthesized the same which had same physical characteristics identical to that of natural product.





CHAPTER III: Synthesis of the ABCD ring framework of the revised structure of azaspiracid-1 

In chapter III the synthesis of the ABCD ring framework of the revised azaspiracid-1 is described. The main differences between the first proposed structure and revised structure are the position of double bond in the A ring (Figure 2). In the revised structure it is between C-7–C-8 instead of C-8–C-9. The stereochemistry of C-14 methyl, D ring, C-20 hydroxyl group and the stereocentres in FGHI rings are enantiomeric to the first proposed structure (Figure 2). The E ring has the same stereochemistry.
 
Section A: This section deals with the synthesis of the ABCD ring framework of the revised structure of azaspiracid-1 by connecting two fragments via C-10 and C-11 bond formation
Disconnection between C-10 and C-11 carbon

The ABCD ring framework (63) of the revised structure was envisaged to be obtained from diketo 64, which could in turn be obtained by a Stetter reaction as shown in Scheme 11.

Synthesis of C-11 to C-20 carbon fragment
The ,-unsaturated ketone 66 (Scheme 12) the enantiomer of compound 8 (Scheme 4) was prepared using L-(+)-DIPT instead of D-(–)-DIPT and AD-mix- instead of AD-mix-.


Synthesis of C-5 to C-8 and C-5 to C-10 fragments
The aldehyde part was prepared from D-(+)-mannitol or from D-(–)-tartaric acid as shown in Scheme 13, initial optimization of the reaction was done using DL-tartaric acid. Acetylenic derivative i.e. C-5 to C-8 fragment was synthesized from D-(–)-tartaric acid.



The Stetter reaction between unstable crude aldehydes (78/83, Scheme 13) obtained by DMP oxidation of the corresponding alcohols (77/82) and ,-unsaturated ketone 66 produced complex mixture of products (Scheme 14).



Section B: This section deals with the synthesis of the ABCD ring framework of the revised structure of azaspiracid-1 by unification of two fragments by C-8 and C-9 bond formation



ABCD ring framework (89) of azaspiracid-1 could be obtained from the precursor 90 by deprotection of protection groups followed by tandem bis-spiroketalisation in the presence of proton source. The precursor 90 was thought to be obtained from lactol 91. Compound 91 in turn could be accessed from homo allylic alcohol 93 via compound 92. The compound 93 would be traced to epoxy alcohol 94 (Scheme 15).

Synthesis of the ABCD ring framework fragment of the azaspiracid-1
In Scheme 16, the synthesis of building block 92, trans substituted tetrahydrofuran ring (D ring) of azaspiracid-1 is discussed. The epoxy alcohol 94 was prepared from 1,4- butanediol 95 following routine transformations. The epoxy alcohol was then transformed to diastereomeric bromo acetal 96 in three steps. The bromo acetal 96 on subjecting to stereoselective radical cyclisation with n-Bu3SnH and AIBN in refluxing benzene followed 


by Jones oxidation produced lactone 97. Reductive opening of dichloro derivative of lactone with Li in refluxing THF furnished acetylenic alcohol 98 with concomitant removal of benzyl group. The TBS ether of 98 was then treated with n-BuLi at – 78 °C, resultant borate was then reacted with chiral epoxide 99 to afford homo propargylic alcohol 100. Attempted reduction of the triple bond under different reaction conditions (Red-Al in THF reflux, LAH in ether reflux, LAH in THF reflux, LAH in mixed THF: DME at reflux) failed to produce trans homo allyl alcohol. Under Birch reduction conditions the conversion was not good. The triple bond, after much experimentation, was reduced at high temperature (155 °C) using LAH in diglyme and THF (8: 1) as a mixed solvent with simultaneous deprotection of TBS group to produce the trans homo allyl alcohol 93 after acetonide protection of resulting triol. The secondary hydroxyl group of 93 was subjected to tosylation (TsCl, Et3N) followed by subjection of dihydroxylation of resulting tosyl derivative with AD-mix- produced the trans 2,5-substituted tetrahydrofuran ring 92. 



In Scheme 17, the synthesis of precursor 104 required for the synthesis of the ABCD ring framework of azaspiracid-1 is discussed. The MOM ether of 92 was transformed to -lactol 101 by deprotection of acetonide followed by selective oxidation of primary hydroxyl group with IBX using Corey protocol. The lactol 101 was then treated with one carbon Wittig ylide (Ph3PCH3I, NaNH2 in ether) and the resulting hydroxyl olefin upon TBS protection (TBS-OTf, 2,6-lutidine) of secondary hydroxyl group followed by epoxidation of olefin with m-CPBA furnished the epoxide 102 (1:1 diastereomer). The epoxide 102 was then treated with acetylenic compound 87 (prepared from D-()-tartaric acid as shown in Scheme 13) using Yamaguchi protocol (n-BuLi, BF3.OEt2, – 78 °C) to afford diol 103 after TBS deprotection {CSA (cat), MeOH}. The partial reduction of triple bond of diol 103 was achieved using Lindlar's catalyst in ethanol, in the presence of quinoline as a catalyst poison under H2 atmosphere (balloon) to give cis-olefin, which on Dess-Martin periodinane oxidation of 1,4-diol produced the 1,4-diketo precursor 104 of the ABCD ring framework of azaspiracid-1. When 104 was treated under different reaction condition such that both MOM and TBDPS groups underwent deprotection simultaneously and further underwent spiroketalisation to yield the ABCD ring framework (89) of azaspiracid-1, was not isolated though starting material was consumed (6N HCl in THF at heating condition, 6N HCl in MeOH at 0 °C to rt, PPTS in t-butanol under heating condition, CeCl3/NaI in t-butanol at 80 °C). 
After unsuccessful attempts to synthesize the ABCD ring framework of azaspiracid-1, the precursor 90 was made in such a manner that the protecting groups were removed under very mild acidic conditions (Lewis acid or protic acid) i.e. P = TBS (90, Scheme 15) which can be easily deprotected under very mild condition (CSA) to produce the ABCD ring framework (89) of azaspiracid-1 under this reaction conditions. To complete the synthesis compound 105 was prepared by protection of secondary hydroxyl of 92 as its TBS ether (TBS-OTf, 2,6-lutidine), transformed it to epoxide 106 and then into diketo compound 108, the precursor of the ABCD ring framework (89) of azaspiracid-1 as shown in Scheme 18. When the TBS groups were subjected to deprotect using CSA in methanol, the TBS groups were deprotected cleanly and the resulting diol 109 underwent cyclization to the thermodynamically stable spiroketal 89.
Stereochemistry of the ABCD ring framework 89 of azaspiracid-1 was determined by extensive NMR studies. Two-dimensional experiments like, total correlation spectroscopy (TOCSY) and double quantum filtered correlation spectroscopy (DQFCOSY) were used to make 1H spectral assignments. To obtain the spatial proximity of the protons nuclear Overhauser effect spectroscopy (NOESY) experiment was used, which in addition also provided further support in the assignments.

          







nOe correlation of compound 89
What are marine shellfish poisoning?
Some shellfish such as cockles, mussels and oysters feed on microscopic algae and some of these algae produce toxins accumulating in shellfish which effect on human health and are responsible for widespread killing of sea fish, marine mammals and birds.1

Different type of shellfish poisoning:
There are different types of seafood poisonings found like (1) Paralytic Shellfish Poisoning (PSP), (2) Neurotoxin Shellfish Poisoning (NSP), (3) Amnesic Shellfish Poisoning (ASP), (4) Diarrhetic Shellfish Poisoning (DSP) and (5) Azaspiracid Shellfish Poisoning (AZP).

1). Paralytic Shellfish Poisoning (PSP):2 
This toxin found in the summer months on the east coast (Newfoundland to Massachusetts), on the west coast (Alaska to California) and along the St. Lawrence River of North America in shellfish contaminated by saxitoxins accumulating in mussels, clams, cockles, scallops, oysters, crabs and lobsters. PSP causes tingling or numbness of the face, arms and legs, followed by headache, dizziness, nausea and muscular in-coordination, in major cases may cause muscle paralysis and respiratory failure.
The toxin causing the PSP syndrome was given the name Saxitoxin3 (STX, Figure 1), from the species of the bivalve mollusk (Saxidomus giganteus) from which it was extracted (Schantz, 1984). In terms of their basic structure, saxitoxins have a tetrahydropurine molecule with two guanidine groups; one of these is affected by the blocking of Na+ channels in the cell membrane.4

2). Neurotoxin Shellfish Poisoning (NSP):5 
NSP toxin found in oysters, clams and mussels harvested along the Atlantic coast of the southern US and the Gulf of Mexico, contaminated by brevetoxins. General symptoms are numbness, tingling in the mouth, arms and legs, incoordination, stomach upset and severe mussel aches. Examples of NSP toxins are depicted below.
Brevitoxin B (Figure 2) was isolated in 1981 by Nakanishi et al. from red tide dinoflagellate, Gymnodinium breve. It was potent, lipid soluble neurotoxin that binds to sodium channels of neurons keeping them open, causing depolarization of the cell membrane.6
Brevitoxin A (Figure 3) the most potent ichthyotoxin was isolated in 1986 (Shimizu et al.), from Gymnodinium breve.




3). Amnesic Shellfish Poisoning (ASP):7 
ASP toxin, domoic acid (Figure 4), which causes nausea, vomiting and diarrhea is accumulating mainly in clams, mussels, oysters and scallops. It also causes permanent short-term memory loss, paralysis and disorientation. Domoic acid8 (ASP) is an amino acid phycotoxin (algal toxin) found associated with certain algal blooms. In 1958, domoic acid was originally isolated from the Red alga called "Doumoi' or "Hanayanagi" in Japan. In the brain, domoic acid especially damages the hippocampus and amygdaloidal.



4). Diarrhetic Shellfish Poisoning (DSP):9
DSP occurs seasonally in Europe and Japan by eating shellfish contaminated with the toxin, okadaic acid. DSP is not lethal for humans but nonetheless it causes a significant health problem. The poisoning symptoms are of a gastrointestinal nature and include diarrhea, nausea, vomiting and abdominal cramps.
Pectenotoxins (PTX)10 is a group of cyclic polyethers of marine origon, first isolated by Yasumoto and colleagues (1985). PTX, a cyclic ester associated with cases of diarrhea so serious that require admission to hospital (Figure 5).
Okadaic acid (Figure 6), liposoluble compound, was discovered initially in Prorocentrum lima, a benthic and epiphytic dinoflagellate (Murakami et al.11 1982) and later from dinoflagellates of the genus Dinophyis (Yasumoto et al.12 1980; Lee et. al.13 1989). Okadaic acid is a complex natural product isolated by Tachibana et al. from the marine sponges Halichondria okadai and Halichondria melanodocia. Okadaic acid and its derivatives are soluble in fats, can easily cross the cell membrane (Suganuma et al.14 1989). Okadaic acid also exhibits powerful biological activities, it is not only a selective protein phosphates inhibitor but also interacts with cellular regulatory processes and is a potent tumor promoter. (-) Gymnodimine15 (Figure 6) is a member of a unique class of marine toxins possessing imines within a spirocyclic array within macrocycless that contained a polyether sub unit. Yessotoxin16 (Figure 7) was isolated for the first time in Japan from the digestive glands of the comb Pactinopecten Yessoensis (Murata et. al.17 1987). Yessotoxins is a polyether made up of a series of 11 cyclic trans fused rings, an unsaturated terminal chain with 9 carbon atoms and on the opposite side two sulphated alcoholic groups.





5). Azaspiracid Shellfish Poisoning (AZP): 
Azaspiracid (Figure 8) is a marine natural product, shellfish toxin, isolated from the blue mussel Mytius edulis collected in Killary Harbour, Ireland. The first episode of azaspiracid poisoning was reported by McMahon and Silke18 in 1996 in the Netherlands, where people ate mussels imported from Ireland (Killary Bay) complained of gastrointestinal symptoms and serious diarrhea. Yasumoto19 and co-worker reported the isolation of azaspiracid-1 (containing single azaspir ring and one carboxylic acid group) and proposed the structure. Ten more closely related analogues of azaspiracid20,21,22 were isolated as azaspiracid-2, azaspiracid-3, azaspiracid-4, azaspiracid-5, azaspiracid-6, azaspiracid-7, azaspiracid-8, azaspiracid-9, azaspiracid-10 and azaspiracid-11 (Figure 8). The human and environment hazardness of azaspiracid has drawn the much more attention towards its synthesis.21 Its effect on human is different than other marine toxins. The symptoms resembled to those of diarrheic shellfish poisoning (DSP) but the major DSP toxins such as okadaic acid and dinophysistoxins are very low in the contaminated mussels. Extensive bioassays performed on azaspiracid have demonstrated that the effects of the toxins when administrated to mice are distinct from those caused by other marine toxins, hence, azaspiracid poisoning (AZP) defines a new type of neuroxicity associated with this environmental contaminant. So azaspiracid is a shellfish toxin, marine biotoxin, causes serious injury to the digestive tracts, liver, pancreas thymus and spleen in mice. Azaspiracid 1-3 shown toxicity in vitro with lethal doses in mice of 0.2,0.11 and 0.14-mg/kg respectively.
Mass spectrometric and extensive NMR spectroscopic analysis22 revealed that azaspiracid-1 is an unprecedented array of polycyclic, spiro fused ring systems having an amino acid with 40 carbons backbone with 47 carbons, 20 stereo centered and 9 ring with three spiro linkages. Azaspiracid is dinoflagellate in nature, due to highly oxygenated polyether structure. Azaspiracid contains trioxadispiroketal system fused to tetrahydrofuran moiety (ABCD ring), azaspiroring fused to a 2,9-dioxabicyclo[3.3.1]nonane system (FGHI ring), six membered hemiketal bridge (E ring) and γ,δ-unsaturated carboxylic acid. The complex structural framework, stereochemical ambiguity, unique architecture, biological activity and scarcity make azaspiracid-1 a challenging task for synthetic chemists to synthesize it. Total synthesis of azaspiacid-1 by Nicolaou et al.31 revealed that the original structure proposed by Yasumoto et al. was not correct and finally Nicolaou groups synthesize the azaspiracid-1 and revised the structure for azaspiracid-132 (Figure 9).
In November 1995, at least eight people in the Netherlands became ill after eating Mussels (Mytilus edulis) cultivated at Killary Harbour, Ireland. Although the symptoms resembled those of diarrhoetic shellfish poisoning (DSP), concentration of the major DSP toxins were very low. The known organisms producing DSP toxins were not observed in water samples collected at that time. In addition, a slowly progressing paralysis was observed in the mouse assay using the mussel extract. These neurotoxin symptoms were quite different from typical DSP toxicity. It was then that of azaspiracid (formerly called Killary toxin-3 or KT3) was identified and the new toxic syndrome was called azaspiracid poisoning (AZP).
Satake et al. (1998) elucidated the structure of azaspiraicd after human intoxication due to the consumption of contaminated Irish mussels. Azaspiracids differ from any of the previously known nitrogen-containing toxins found in shellfish of dinoflagellates (e.g. prorocentrolide, pinnatoxin, gymnodimine and the spirolides). Azaspiracids (AZAs) have unique spironing assemblies, a cyclic amine instead of a cyclic imine group and a carbocyclic or lactone ring is absent (Satake et al.1998).
Satake et al. (1998) reported that mussel extracts did not show a significant decrease of toxicity when the extract was heated at 5 °C for 150 minutes in 1.0N acetic acid/methanol or 1.0 N ammonium hydroxide solution and no significant change in toxicity occurred in solution during storage. Therefore AZAs are assumed to be relatively stable compounds.
Typically, polyether toxins are concentrated in the digestive glands of shellfish but this is not always the situation with azaspiracids. Azaspiracid and its methyl and demethyl analogues, AZA2 and AZA-3 respectively, are not confined to the hepatopancreas but are also distributed throughout shellfish tissues. The toxin profiles differed significantly in various mussel tissues with AZA as the predominant toxin in the digestive glands and AZA-3 and an isomer of AZA predominant in the remaining tissues. However, the transportation of these toxins to period of shellfish intoxication is likely due to a low rate of natural extraction process of the toxins. This leads to the speculation the polar amino acids and the non-polar polyether regions of azaspiracid impart detergent properties to this molecule. The ease with which azaspiracids can move through different polarities probably plays a significant role in the increased penetration of these toxins in shellfish and mammalian tissues. There can be a significant variation in the total level of AZAs in mussels from different sites in the same cultivation region.
Acute oral studies with azaspiracid were performed in mice. During the course of toxin purification, the major toxin was concentrated in a lipid fraction coded KT3 (Ito et al.23 2000). By oral administration (by gavage) of 60 l of this KT3 fraction mice did not show any clinical changes during 24 hours. At autopsy after four hours, active secretion of fluid from the ileum and debris of necrotizing epithelial cells from upper portion of the villi were observed in the lumen (SEM) and after eight hours, erosion of the villi from the top resulted in the shortened villi, and prominent accumulation of fluid was observed accompanying edema in the lamina propria. Then after 24 hours, these changes were not observed but epithelial cells of adjacent villi were fused to each other (Ito et al. 1998).

Name      R1      R2    R3      R4
AZA-1 :  H     H     Me    H
AZA-2 :  H     Me   Me    H
AZA-3 :  H      H     H      H
AZA-4 :  OH   H     H      H
AZA-5 :  H      H     H      OH
AZA-6 :  H      Me   H      H
AZA-7 :  OH   H     Me    H
AZA-8 :  H      H     Me    OH
AZA-9 :  OH   Me   H      H
AZA-10: H      Me   H      OH
AZA-11: OH   Me   Me    H






Others marine shellfish toxins:
Pinnatoxin A24 (Figure 10), marine-derived 27 membered macrocycle containing a spiro-linked cyclic imine along with trioxadispiro and bicycloacetal substructures, having shellfish poisoning was isolated (Pinna muricata) and characterized by Uemura et al. (1995).

Spirolides,25(Figure 11) a novel family of marine macrolides were isolated from mussels (Mytilus edulis) and scallops (Placopecten magellanicus) in Nova Scotia, Canada, in 1995. The spirolides are metabolites of the marine dinoflagellate Alexandrium ostenfeldii and exhibit more structural homology with microlides of similar origin gymnodimine. In common with the pinnatoxins, the spirolides possess a seven-membered spirolinked cyclic imine together with a novel bis-spiroacetal ring system.





Shellfish Toxins:

Toxin group	ASP	DSP	PSP	AZP	NSP
Principal Toxins	Domoic acid	Okadaic acid, Dinophysistoxins, Pectenotoxins and Yessotoxins.	Saxitoxins, Gonyautoxins C-Toxins.	Azaspiracid	Brevetoxins
Origin	Red macro algae and Diatoms.	Marine Dinoflagellates.	Marine Dinoflagellates.	Marine Dinoflagellates.	Marine Dinoflagellates.
Symptoms	Symptoms include nausea, vomiting, diarrhea, amnesia and respiratory depression.	Symptoms include nausea, vomiting, diarrhea and abdominal pain.	Tingling/ numbness in mouth, ataxia, dizziness, headache, respiratory distress and muscular paralysis.	Similar symptoms to DSP+ headaches & Cramps.	Numbness,tingling in the mouth, arms and legs, in coordination stomach upset and severe muscles aches. 
Outbreaks	Eastern Canada (1987): Human poisoning (104 people)-2 deaths.	UK (1998): 49 patients diagnosed as suffering from DSP resulting from high Okadaic acid level in mussels. 	Annually results in approximately 300 deaths.	Toxic outbreak in the Netherlands due to consumption of Irish mussels.	Gulf of Mexico, Atlantic coast of the southern USA
EU Limits	20mg/kg	160mg/kg (OA, DTXs & PTXs), 1 mg/kg YTX	0.8 mg/kg of tissue.	160 mg/kg	-






Previous approaches towards synthesis of azaspiracid-1:

Carter's Approach: 
Carter et al26 synthesized the ABCD ring framework of azaspiracid-1 (first proposed structure) by coupling reaction between sulfone 1 and aldehyde 2, but the stereochemistry of final ABCD ring framework was found cisoidal, not the required transoidal (Scheme 1). The sulphoxide27 effect is observed to form unnatural transoidal conformation (Scheme 2). 




Carter’s approach towards the ABCD ring framework of azaspiracid-1 (revised structure):
Carter et al.28 synthesized the ABCD ring framework (3) of azaspiracid-1 (revised) through coupling reaction between lactol 4 and phosphonate 5. Compound 4 was obtained by coupling between sulfone 6 with aldehyde 7. The compound 6 was obtained from L-malic acid (Scheme 3).




Forsyth's Approach:
Forsyth et al.29 synthesized the ABCD framework ring (1) of azaspiracid-1 (first proposed structure) from fragment 5. The compound 5 was prepared by coupling of aldehyde 3 with acetylenic compound 2. The aldehyde 3 was obtained from lactone 3. The stereochemistry of ABCD (1) ring was found to be undesired cisoidal (Scheme 4).





Nicolaou’s Approach: 
Nicolaou et al.30 initially synthesized the ABCD ring framework of first proposed structure of azaspiracid-1. The structure showed the cisoidal configuration (C-9 sulfoxide as an auxiliary group to control the C-13 spiro center, Scheme 5) then they synthesized the desired transoidal ring by hydrogen bonding influence to control C-13 stereocentre Scheme 6. The total synthesis of Azaspiracid-131 was completed (Scheme 6) and the structure was found to be wrong. Then after immense synthetic effort they proposed the new structure for azaspiracid-1. They synthesized the revised structure of azaspiracid-132 (Scheme 7) and found its physical and spectroscopic characteristics matched with natural product.   

Synthesis of ABCD ring framework of azaspiracid-1 (first proposed structure)





Total synthesis of azaspiracid-1 (first proposed structure)




Total synthesis of azaspiracid-1 (revised structure)



Nishiyama's Approach: 
Nishiyama et al.33 synthesized the ABCD ring framework of azaspiracid-1 (originally proposed) starting with L-malic acid, which was converted to epoxide. The tetrahydrofuran ring was prepared from epoxide, which was transformed to lactone. The lactone then converted to thioacetal, which after treatment with TMS-OTf furnished the ABCD ring of azaspiracid-1 (Scheme 8) having undesired stereochemistry at C-13 stabilised by two anomeric effects.



Nishiyama et al.34 synthesized the transoidal conformation of ABCD ring framework of azaspiracid-1 (Scheme 9) regulating by sulphur bridge.
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